| |
 |
|
|
|
|
 Patent News |
 |
| Subject : Boryung Wins Patent Suit Against Sanofi-Aventis |
| Date |
2010-05-28 |
Visit |
5261 |
According to a statement by Boryung Co., Ltd., it won the invalidation trial against Sanofi-Aventis regarding its carcinostatis substance ‘Taxotere (docetaxel).’
The Korean Intellectual Property Tribunal (KIPT) found in favor of Boryung, stating that Sanofi-Aventis’s patent did not meet the conditions required for a valid patent because there was no submitted information regarding data, physical/chemical characteristics, purpose, or effects that may be used to verify the generation of docetaxel (ingredient for Taxotere).
As a result, Sanofi-Aventis’s patent was invalidated.
The pharmaceutical industry expects an increase in generic sales of products that utilize docetaxel as its main ingredient.
|
| |
|
|
|
|
 |
DOWON INTERNATIONAL
5F. Shinwon Bldg. 823-14, Yeoksam-dong, Kangnam-ku, SEOUL, 135-080
KOREA
PHONE : 82-2-501-3106 FAX : 82-2-501-3109 e-mail : patyellow@dowon.com
|
|
|
|
|
